Merck, R2520-20KU, Ribonuclease inhibitor human

General description
Ribonuclease inhibitor works to inhibit RNase activity by forming a tight, non-covalent 1:1 complex. It is human placenta. It inhibits RNases A, B, and C. It will not inhibit RNases H, 1, T1, S1 Nuclease, SP6, T7 RNA Polymerase, T3 RNA Polymerase, AMV Reverse Transcriptase, M-MLV Reverse Transcriptase, or Taq Polymerase. The inhibitor can be removed by phenol extraction or by heating to 65°C for 10 minutes.
Application
Suitable for use in
in vitro inhibition of ribonucleases
cDNA synthesis
RT-PCR
in vitro transcription and translation

Useful for in vitro inhibition of ribonucleases, including procedures like cDNA synthesis, RT-PCR, and in vitro transcription and translation.
Biochem/physiol Actions
Inhibits RNase by forming a tight, non-covalent 1:1 complex.
Inhibits RNase by forming a tight, non-covalent 1:1 complex. Also inhibits angiogenin, a neovascularization promoter which is homologous with RNase A.
Physical form
Solution in 50% glycerol, 20 mM HEPES-KOH, pH 7.6, 50 mM KCl and 8 mM DTT
Other Notes
One unit will reduce the activity of 5 ng of ribonuclease A by 50% in a cytidine 2′:3′-cyclic monophosphate system.
Ribonuclease Inhibitor is provided as a solution in 20 mM HEPES-KOH( pH 7.6), 50 mM KCl, 8 mM DTT and 50% glycerol.
Solution in 50% glycerol, 20 mM HEPES-KOH, pH 7.6, 50 mM KCl and 8 mM DTT
This inhibitor of RNase activity is isolated from human placenta and supplied as a buffered aqueous glycerol solution.